Product News: CN Bio’s PhysioMimix technology receives FDA recognition
13 Jan 2021
CN Bio, one of the leading developers of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, has announced the publication of co-authored research with the U.S. Food and Drug Administration (FDA)1. The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using CN Bio’s proprietary PhysioMimix™ system is appropriate for use in drug safety and metabolism applications, evidencing its enhanced performance versus standard techniques. The publication substantiates the Company’s position as a leader in the field with reliable and robust cutting-edge technology, ready for widespread adoption across the pharmaceutical industry.